%PDF-1.4
%
71 0 obj
<>
endobj
68 0 obj
<>
endobj
128 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-09-13T13:47:44Z
2024-03-28T02:26:04-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T02:26:04-07:00
application/pdf
Heather
2003-669.oct
uuid:c99571f1-1dd1-11b2-0a00-290a275dc400
uuid:c99571f3-1dd1-11b2-0a00-810000000000
endstream
endobj
57 0 obj
<>
endobj
58 0 obj
<>
endobj
72 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 41 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
28 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
31 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 51 0 R/Type/Page>>
endobj
154 0 obj
[158 0 R]
endobj
155 0 obj
<>stream
q
0 0 612 783 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6283 0.7779 -0.7779 0.6283 8.2321 49.765 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 783 m
0 783 l
f
q
-1 784 587 -785 re
W n
q
0 783.03 612 -783 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 60 732.5293 Tm
(erythematosus. Q J Med 1993;86:447-58.)Tj
-1.3 -1.25 Td
[(9.)-825.1 (Disease activity in systemic lupus erythematosus: report of the)]TJ
1.3 -1.25 Td
[(Consensus Study Group of the European )17.7 (W)79.9 (orkshop for)]TJ
0 -1.25 TD
(Rheumatology Research. II. Identification of the variables indicative)Tj
T*
(of disease activity and their use in the development of an activity)Tj
T*
[(score. )17.7 (The European Consensus Study Group for disease activity in)]TJ
T*
(SLE. Clin Exp Rheumatol 1992;10:541-7.)Tj
-1.8 -1.25 Td
[(10.)-550.1 (Morimoto C, Sano H, )54.8 (Abe )17.7 (T)74 (, Homma M, Steinber)17.7 (g )54.8 (AD. Correlation)]TJ
1.8 -1.25 Td
(between clinical activity of systemic lupus erythematosus and the)Tj
T*
[(amounts of DNA)-220.2 (in DNA/anti-DNA)-220.2 (antibody immune complexes. )]TJ
T*
(J Immunol 1982;139:1960-5.)Tj
-1.7631 -1.25 Td
[(1)36.8 (1)-0.1 (.)-550.1 (Bencivelli )17.7 (W)91.8 (,)-0.1 ( )17.7 (V)59.8 (itali C, Isenber)17.7 (g DA, et al. Disease activity in)]TJ
1.7631 -1.25 Td
(systemic lupus erythematosus: report of the Consensus Study Group)Tj
T*
[(of the European )17.7 (W)79.9 (orkshop for Rheumatology Research. III.)]TJ
T*
(Development of a computerized clinical chart and its application to)Tj
T*
[(the comparison of dif)17.7 (ferent indices of disease activity)64.8 (. )17.7 (The European)]TJ
T*
[(Consensus Study Group of Disease )54.8 (Activity in SLE. Clin Exp)]TJ
T*
(Rheumatol 1992;10:549-54.)Tj
-1.8 -1.25 Td
[(12.)-550.1 (Petri M, Hellmann D, Hochber)17.7 (g MC. )17.7 (V)110.8 (alidity and reliability of)]TJ
1.8 -1.25 Td
(lupus activity measures in the routine clinic setting. J Rheumatol)Tj
0 Tc 0 Tw T*
(1992;19:53-9.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(13.)-550.1 (Committee on Prognosis Studies in SLE. Prognosis studies in SLE:)]TJ
1.8 -1.25 Td
[(an activity index [abstract]. )54.8 (Arthritis Rheum 1986;29 Suppl:S93.)]TJ
-1.8 -1.25 Td
[(14.)-550.1 (Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,)]TJ
1.8 -1.25 Td
(and the Committee on Prognosis Studies in SLE. Derivation of the)Tj
T*
[(SLEDAI. )54.8 (A)-220.1 (disease activity index for lupus patients. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1992;35:630-40.)Tj
-0.00011 Tc -1.8 -1.25 Td
[(15.)-550.1 (Liang MH, Socher SA, Larson MG, Schur PH. Reliability and)]TJ
1.8 -1.25 Td
(validity of six systems for the clinical assessment of disease activity)Tj
T*
[(in systemic lupus erythematosus. )54.8 (Arthritis Rheum 1989;32:1)36.8 (107-18.)]TJ
-1.8 -1.25 Td
[(16.)-550.1 (Gladman DD, Goldsmith CH, Urowitz MB, et al. Crosscultural )]TJ
1.8 -1.25 Td
(validation and reliability of 3 disease activity indices in systemic)Tj
T*
[(lupus erythematosus. J Rheumatol 1992;19:608-1)36.8 (1.)]TJ
-1.8 -1.25 Td
[(17.)-550.1 (Gladman DD, Goldsmith CH, Urowitz MB, et al. Sensitivity to)]TJ
1.8 -1.25 Td
(change of 3 systemic lupus erythematosus disease activity indices:)Tj
T*
(International validation. J Rheumatol 1994;21:1468-71.)Tj
-1.8 -1.25 Td
[(18.)-550.1 (W)79.9 (ard MM, Marx )54.8 (AS, Barry NN. Comparison of the validity and)]TJ
1.8 -1.25 Td
(sensitivity to change of 5 activity indices in systemic lupus )Tj
T*
(erythematosus. J Rheumatol 2000;27:664-70.)Tj
-1.8 -1.25 Td
[(19.)-550.1 (Fellows of Harvard College. SLE )54.8 (Activity Measure-Revised)]TJ
1.8 -1.25 Td
(\(SLAM-R\). Revised 1998.)Tj
-1.8 -1.25 Td
[(20.)-550.1 (Bae S-C, Koh H-K, Chang D-K, Kim M-H, Park J-K, Kim S-Y)128.8 (.)]TJ
1.8 -1.25 Td
(Reliability and validity of systemic lupus activity measure-revised)Tj
T*
(\(SLAM-R\) for measuring clinical disease activity in systemic lupus)Tj
T*
(erythematosus. Lupus 2001;10:405-9.)Tj
-1.8 -1.25 Td
[(21.)-550.1 (Petri M, Buyon J, Skovron ML, Kim M, for the SELENA)-220.2 (Study)]TJ
1.8 -1.25 Td
[(Group. Reliability of SELENA)-220.2 (SLEDAI and flare as clinical trial)]TJ
T*
[(outcome measures [abstract]. )54.8 (Arthritis Rheum 1998;41 Suppl:S218.)]TJ
-1.8 -1.25 Td
[(22.)-550.1 (FitzGerald JD, Grossman JM. )17.7 (V)110.8 (alidity and reliability of )]TJ
1.8 -1.25 Td
(retrospective assessment of disease activity and flare in )Tj
T*
(observational cohorts of lupus patients. Lupus 1999;8:638-44.)Tj
-1.8 -1.25 Td
[(23.)-550.1 (Gladman DD, Iba\226ez D, Urowitz MB. Systemic lupus )]TJ
1.8 -1.25 Td
(erythematosus disease activity index 2000. J Rheumatol)Tj
0 Tc 0 Tw T*
(2002;29:288-91.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(24.)-550.1 (Guzman J, Cardiel MH, )54.8 (Arce-Salinas )54.8 (A, S\207nchez-Guerrero J,)]TJ
1.8 -1.25 Td
(Alarc\227n-Segovia D. Measurement of disease activity in systemic)Tj
T*
(lupus erythematosus. Prospective validation of 3 clinical indices. )Tj
T*
(J Rheumatol 1992;19:1551-8.)Tj
-1.8 -1.25 Td
[(25.)-550.1 (Alarcon GS, Roseman JM, Bartolucci )54.8 (AA, et al. Systemic lupus)]TJ
1.8 -1.25 Td
(erythematosus in three ethnic groups: II. Features predictive of)Tj
T*
[(disease activity early in its course. )54.8 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
[(1998;41:1)36.9 (173-80.)]TJ
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(26.)-550.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
1.8 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw 31.2 80 Td
[(27.)-550.1 (Hochber)17.7 (g MC. Updating the )54.8 (American College of Rheumatology)]TJ
1.8 -1.25 Td
(revised criteria for the classification of systemic lupus )Tj
T*
[(erythematosus [letter]. )54.8 (Arthritis Rheum 1997;40:1725.)]TJ
-1.8 -1.25 Td
[(28.)-550.1 (Aarden LA, De Groot ER, Feltkamp )17.7 (TEW)91.7 (. Immunology of DNA.)]TJ
-0.0002 Tc 0 Tw 1.8 -1.25 Td
(III. )Tj
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 1.5233 0 Td
(Crithidia luciliae,)Tj
/T1_1 1 Tf
7.4663 0 Td
(a simple substrate for the determination of)Tj
-8.9895 -1.25 Td
[(anti-dsDNA)-220.2 (with the immunofluorescence technique. )54.8 (Ann NY)-183.3 (Acad)]TJ
T*
(Sci 1975;254:505-15.)Tj
-1.8 -1.25 Td
[(29.)-550.1 (Bland JM, )54.8 (Altman DG. Statistical methods for assessing agreement)]TJ
1.8 -1.25 Td
(between two methods of clinical measurement. Lancet )Tj
0 Tc 0 Tw T*
(1986;1:307-10.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(30.)-550.1 (Abrahamowicz M, Fortin PR, Du Ber)17.7 (ger R, Nayak )17.7 (V)128.9 (, Neville C,)]TJ
1.8 -1.25 Td
[(Liang MH. )17.7 (The relationship between disease activity and expert)]TJ
T*
[(physician\325)54.8 (s decision to start major treatment in active systemic lupus)]TJ
T*
[(erythematosus: )54.8 (A)-220.1 (decision aid for development of entry criteria for)]TJ
T*
(clinical trials. J Rheumatol 1998;25:277-84.)Tj
-1.8 -1.25 Td
[(31.)-550.1 (Guzman J, Cardiel MH, )54.8 (Arce-Salinas )54.8 (A, )54.8 (Alarc\227n-Segovia D. )17.7 (The)]TJ
1.8 -1.25 Td
(contribution of resting heart rate and routine blood tests to the )Tj
T*
(clinical assessment of disease activity in systemic lupus)Tj
T*
(erythematosus. J Rheumatol 1994;21:1845-4.)Tj
-1.8 -1.25 Td
[(32.)-550.1 (Rojas-Serrano J, Cardiel MH. Lupus patients in an emer)17.7 (gency unit.)]TJ
1.8 -1.25 Td
[(Causes of consultation, hospitalization and outcome. )54.8 (A)-220.1 (cohort study)64.8 (.)]TJ
0 Tc T*
(Lupus 2000;9:601-6.)Tj
-0.00011 Tc -1.8 -1.25 Td
[(33.)-550.1 (Hernandez-Cruz B, )17.7 (T)69.9 (apia N, )17.7 (V)59.8 (illa-Romero )54.8 (AR, Reyes E, Cardiel)]TJ
1.8 -1.25 Td
(MH. Risk factors associated with mortality in systemic lupus )Tj
T*
[(erythematosus. )54.8 (A)-220.1 (case-control study in a tertiary care center in)]TJ
T*
[(Mexico City)64.8 (. Clin Exp Rheumatol 2001;19:395-401.)]TJ
-1.8 -1.25 Td
[(34.)-550.1 (Arce-Salinas )54.8 (A, Cardiel MH, Guzm\207n J, )54.8 (Alcocer)19.7 (-V)110.8 (arela J. )17.7 (V)110.8 (alidity)]TJ
1.8 -1.25 Td
(of retrospective disease activity assessment in systemic lupus)Tj
T*
(erythematosus. J Rheumatol 1996;23:846-9.)Tj
-1.8 -1.25 Td
[(35.)-550.1 (Massardo L, Bur)17.7 (gos P)110.7 (, Martinez ME, et al. )54.8 (Antiribosomal P)-238.2 (protein)]TJ
1.8 -1.25 Td
(antibodies in Chilean SLE patients: no association with renal)Tj
T*
[(disease. Lupus 2002;1)36.8 (1:379-83.)]TJ
-1.8 -1.25 Td
[(36.)-550.1 (Petri M, Genovese M, Engle E, Hochber)17.7 (g MC. Definition, )]TJ
1.8 -1.25 Td
(incidence, and clinical description of flare in systemic lupus )Tj
T*
[(erythematosus. )54.8 (A)-220.1 (prospective cohort study)64.8 (. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1991;34:937-44.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(37.)-550.1 (W)79.9 (alz LeBlanc BAE, Gladman DD, Urowitz MB. Serologically)]TJ
1.8 -1.25 Td
(active clinically quiescent systemic lupus )Tj
T*
(erythematosus \321 predictors of clinical flares. J Rheumatol)Tj
0 Tc 0 Tw T*
(1994;21:2239-41.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(38.)-550.1 (Zonana-Nacach )54.8 (A, Salas M, S\207nchez ML, Camar)17.7 (go-Coronel )54.8 (A,)]TJ
1.8 -1.25 Td
(Bravo-Gatica C, Mintz G. Measurement of clinical activity of)Tj
T*
[(systemic lupus erythematosus and laboratory abnormalities: )54.8 (A)]TJ
T*
[(12-month prospective study)64.8 (. J Rheumatol 1995;22:45-9.)]TJ
-1.8 -1.25 Td
[(39.)-550.1 (Ho )54.8 (A, Magder LS, Barr SG, Petri M. Decreases in )]TJ
1.8 -1.25 Td
[(anti-double-stranded DNA)-220.2 (levels are associated with concurrent)]TJ
T*
[(flares in patients with systemic lupus erythematosus. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2001;44:2342-9.)Tj
-0.00011 Tc -1.8 -1.25 Td
[(40.)-550.1 (Ho )54.8 (A, Barr SG, Magder LS, Petri M. )54.8 (A)-220.1 (decrease in complement is)]TJ
1.8 -1.25 Td
(associated with increased renal and hematologic activity in patients)Tj
T*
[(with systemic lupus erythematosus. )54.8 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(2001;44:2350-7.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(41.)-550.1 (Fortin PR, )54.8 (Abrahamowicz M, Clarke )54.8 (AE, et al. Do lupus disease)]TJ
1.8 -1.25 Td
(activity measures detect clinically important change? J Rheumatol)Tj
0 Tc 0 Tw T*
(2000;27:1421-8.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(42.)-550.1 (Chang E, )54.8 (Abrahamowicz M, Ferland D, Fortin PR, for CaNIOS)]TJ
1.8 -1.25 Td
(Investigators. Comparison of the responsiveness of lupus disease)Tj
T*
(activity measures to changes in systemic lupus erythematosus)Tj
T*
(activity relevant to patients and physicians. J Clin Epidemiol)Tj
0 Tc 0 Tw T*
(2002;55:488-97.)Tj
ET
0 0 0 1 K
42 72 m
546 72 l
S
BT
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 408.3613 53.9844 Tm
(The Journal of Rheumatology 2004; 31:10)Tj
0 Tc 0 Tw -45.7952 -0.0313 Td
(1940)Tj
ET
43 72 m
547 72 l
S
0 0 0 0 k
/GS0 gs
98.25 76.75 396.47 -10.83 re
f*
0.5 w
98.25 76.75 396.47 -10.83 re
S
Q
Q
q
0 0 612 783 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
110.368 69 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
51 0 obj
<>stream
8;Z\6$$+fT%-.@PaR:sFKnDF&D/(GdUrnY.]9XiV"Mn^L?XLP,m4[MeH*%!^n6NcC
r4AM,Sctqun]V((J9!c40?\$!+unJ?p%JV=Qr:b&$H:1U!"#]GG(@b=]DsW+76#,1
>DK]3oWA@hn<"!1.gWmQOmEpa@s?S0B"MqK\@*C\2kZ&XT$I.VD*eK+*U9F0BFMn1
SG-iu:i3&%9_R,UR1jc6]-rB!B/ZDZU:0AW!(KPKU8KI2Be[2'XLON2<(#;:gnrpnFRK2[r9[O_uCM^QmtmFW,@6AO4lsj4WVc,O<8kYea:j"K*2)
Kf'K,QXFfY-ZHK'8KjPcaoJ
PN_Ek5o/B3L+@iT>SX6IlpT_OH>C&UmJ,aBL/Z3%K:5dk>NE.mkmk4RNA6q7e#FPi
nL\9-cO:`D=Tl-P41j7.pF[CQ;PR6ffradTc-g7g/BNV-d\=KrYYo7Y9EbBJ6J,AI
m^L=GlNt!5JR?%=%;Wpa-[^k5@U/+ih<\EP#fEj?D:'W!I>`R/eu);Sq4@\g(PmZ=
0HKd-_,NH@ghSa5X]n7&.lmkDB!2Nh+a_$FN7Iai/=Iq0cZ63-Q\ousM#'bJc\sRR
Z6ip$#_V@ZXOSLq%#;\eV)XD);Xj$X&7J_D47V_bGr:7b(-W8JIa1?tYt-sEPec[X
-(c;)5UjIXiNCk'T'?%gcEOZeYVQa_6]4Qo&2QIoZY5Y>!_`\J9?k%/VNJS*WYeP/
cu7U.LLp8-JK,DVa`Tebm]TN]g;tdKWB1i\>VGR%bPYP*Q)4pL%PJH=BtmAORIO*A
b0^E3!V#0M6[lI0j,r5"%S`8=_0%s
endstream
endobj
55 0 obj
[/Indexed/DeviceRGB 255 54 0 R]
endobj
54 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
113 0 obj
<>
endobj
82 0 obj
<>
endobj
74 0 obj
<>
endobj
98 0 obj
<>
endobj
133 0 obj
<>
endobj
75 0 obj
<>
endobj
90 0 obj
<>stream
HiPSYC1O ݦTDEmnMlY%$ kdiP@ĥ`\h]iaڞ֚J9/}陉:_Lݪ:S☹/CvUۥq)w,c]qvFn3ѱVf+V欻B jA*+Vp&l]a$S5m'O{y&JIRfy5
̖DQ<+HB =5A$NDOْ¼0b/4EߘH8F*KćL U$-L\jj$A N,KSp,ql5
ۀa[),S`u{aaFbXv
{ƭq>jb3!3<פ'YܷKR+-[1/a^|fpO:,rW)\kJ;a?89|G.ܾ#ϱNBQ@VGq
3\+AA-bbmeg5MQz/(4277 nnPn+1A|0ZS(D8&=Y)NyS#7
ukaׁ97=dG>zaӥ#fEuryRWVK9ER+t<¾á4J .S0?%"}FG^ё22DnML_^(7?rF?[`0GpytTJFMgha:ZܴwlG9kmo#ic,?~UⓄw C
UX&Jv=e:g`]fOZT4*x4)EySrdpRgS֥=rH;1{ &Xyd8~Kk SDdErp2Whhz:oxMжD>&l7ҡoZpS0faF̾[-%Se287ٍ:' Ӹs%25_U/Q sW'(6Das4xAr# 6Ij(ܢ~ KG+!iF^tRP,TSssX#`hQePK'p7 m
@?Ct@
]rCw̵o:520]?=nDyp OL7hjdI ϑͧ`z>8DS*Dڋz2S}w`^JzԱzg
X